Move to the content areaUserLogin
 
change language:

メニュー/MENU

TOP　Page
○○学科

▶大学ホームページに戻る

▶Return to University HOME

 

医学部附属病院

Researcher List >> Masato Nakamura
 

Masato Nakamura

 
Avatar
NameMasato Nakamura
URL
AffiliationChiba University
SectionChiba University Hospital, Department of Gastroenterology
Job titleAssistant professor
DegreeMD, PhD(Chiba University)
J-Global ID202101013597803050

Research Interests

 
Liver cirrhosis ,Murine model ,Hepatocellular carcinoma ,Non-alcoholic fatty liver disease

Research Areas

 
  • Life sciences / Nutrition and health science / 
  • Life sciences / Pathobiochemistry / 
  • Life sciences / Gastroenterology / Hepatology

Papers

12345>
 
 
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: The LAUNCH study.
Kazufumi Kobayashi   Sadahisa Ogasawara   Susumu Maruta   Tomomi Okubo   Norio Itokawa   Yuki Haga   Yuya Seko   Michihisa Moriguchi   Shunji Watanabe   Yuki Shiko   Hirokazu Takatsuka   Hiroaki Kanzaki   Keisuke Koroki   Masanori Inoue   Masato Nakamura   Soichiro Kiyono   Naoya Kanogawa   Takayuki Kondo   Eiichiro Suzuki   Yoshihiko Ooka   Shingo Nakamoto   Yosuke Inaba   Masafumi Ikeda   Shinichiro Okabe   Naoki Morimoto   Yoshito Itoh   Kazuyoshi Nakamura   Kenji Ito   Ryosaku Azemoto   Masanori Atsukawa   Ei Itobayashi   Naoya Kato   
Clinical cancer research : an official journal of the American Association for Cancer Research      Oct 2023
BACKGROUND AND AIMS: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from the REFLECT trial. METHODS: This multicenter, nonrandomized, open-label prospective study was condu...
 
Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury.
Takayuki Kondo   Kentaro Fujimoto   Kisako Fujiwara   Sae Yumita   Takamasa Ishino   Keita Ogawa   Miyuki Nakagawa   Terunao Iwanaga   Keisuke Koroki   Hiroaki Kanzaki   Masanori Inoue   Kazufumi Kobayashi   Soichiro Kiyono   Masato Nakamura   Naoya Kanogawa   Sadahisa Ogasawara   Shingo Nakamoto   Tetsuhiro Chiba   Jun Kato   Keiichi Fujiwara   Naoya Kato   
Scientific reports   13(1) 14043-14043   Aug 2023
The pathogenesis of acute liver failure (ALF) involves cell death. Necroptosis is a newly suggested programmed cell death, and receptor-interacting protein kinase 3 (RIPK3) has been reported as a marker for necroptosis. However, there are few repo...
 
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Hiroaki Kanzaki   Sadahisa Ogasawara   Tomomi Okubo   Norio Itokawa   Ryohei Yoshino   Kentaro Fujimoto   Tadayoshi Kogure   Sae Yumita   Takamasa Ishino   Keita Ogawa   Terunao Iwanaga   Miyuki Nakagawa   Kisako Fujiwara   Ryuta Kojima   Keisuke Koroki   Masanori Inoue   Kazufumi Kobayashi   Naoya Kanogawa   Soichiro Kiyono   Masato Nakamura   Takayuki Kondo   Ryo Nakagawa   Shingo Nakamoto   Ryosuke Muroyama   Ei Itobayashi   Masanori Atsukawa   Jun Kato   Naoya Kato   
Drugs - real world outcomes      Jul 2023
BACKGROUND: Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecular tar...
 
Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.
Takayuki Kondo   Kisako Fujiwara   Miyuki Nakagawa   Kentaro Fujimoto   Sae Yumita   Takamasa Ishino   Keita Ogawa   Terunao Iwanaga   Keisuke Koroki   Hiroaki Kanzaki   Masanori Inoue   Kazufumi Kobayashi   Soichiro Kiyono   Masato Nakamura   Naoya Kanogawa   Sadahisa Ogasawara   Shingo Nakamoto   Tetsuhiro Chiba   Jun Kato   Naoya Kato   
Scientific reports   13(1) 11524-11524   Jul 2023
The effect of the combination of atezolizumab and bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC) on pulmonary arterial hypertension (PAH) is unknown. Estimation of PAH by using computed tomography (CT) has recently been proposed. Thus, ...
 
Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma
Ryuta Kojima   Shingo Nakamoto   Tadayoshi Kogure   Yaojia Ma   Keita Ogawa   Terunao Iwanaga   Na Qiang   Junjie Ao   Ryo Nakagawa   Ryosuke Muroyama   Masato Nakamura   Tetsuhiro Chiba   Jun Kato   Naoya Kato   
World Journal of Virology   12(3) 209-220   Jun 2023

Misc.

<12345>
 
 
自己免疫性急性肝不全の長期経過
安井 伸   藤原 慶一   中村 昌人   中本 晋吾   室山 良介   加藤 直也   
肝臓   64(2) 101-101   Feb 2023
 
【肝胆膵がん治療の進歩2023】肝細胞がん 切除不能例に対する免疫療法
弓田 冴   小林 和史   神崎 洋彰   興梠 慧輔   兒島 隆太   井上 将法   中村 昌人   清野 宗一郎   叶川 直哉   近藤 孝行   中川 良   小笠原 定久   中本 晋吾   加藤 直也   
腫瘍内科   31(2) 146-152   Feb 2023
 
Establishment of shear wave elastography measurement methods to improve versatility
藤本健太郎   近藤孝行   近藤孝行   藤原希彩子   小林和史   中村昌人   清野宗一郎   叶川直哉   小笠原定久   中本晋吾   加藤直也   加藤直也   
超音波医学 Supplement   50    2023
 
RESORCE試験に含まれなかった進行肝細胞癌症例に対するレゴラフェニブの安全性と有効性を検証する無作為化第II相試験:REGAIN trial
興梠慧輔   小笠原定久   中川美由貴   藤原希彩子   岩永光巨   神崎洋彰   井上将法   小林和史   清野宗一郎   中村昌人   叶川直哉   近藤孝行   鈴木英一郎   大岡美彦   中本晋吾   千葉哲博   仕子優樹   小澤義人   稲葉洋介   加藤直也   
日本肝がん分子標的治療研究会プログラム・抄録集   28th    2023
 
ナルメフェン投与の単一内科での投与成績と今後の課題
清野宗一郎   小暮禎祥   藤本健太郎   弓田冴   石野貴雅   小川慶太   藤原希彩子   中川美由貴   岩永光巨   興梠慧輔   神崎洋彰   小林和史   井上将法   中村昌人   叶川直哉   近藤孝行   小笠原定久   中本晋吾   千葉哲博   加藤直也   
日本消化器病学会雑誌(Web)   120    2023

Research Projects

 
 
エクソソーム制御による慢性肝疾患関連サルコペニアに対する新規治療法の開発
日本学術振興会: 科学研究費助成事業 若手研究
中村 昌人 
Project Year: Apr 2019 - Mar 2022
 
Development of novel treatment for non-alcoholic steatohepatitis targeting microRNA
Japan Society for the Promotion of Science: Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
Nakamura Masato 
Project Year: Apr 2017 - Mar 2019
Copyright (C) 2021 Chiba University All Rights Reserved.